Study – Clinical Efficacy of Chloroquine derivatives in COVID-19 Infection: Comparative meta-analysis between the Big data and the real world (19,270 patients – is effective)

Source: ScienceDirect | PDF of full Journal Pre-Print

Abstract

In the context of the current COVID-19 pandemic, we conducted a meta-analysis on the effects of chloroquine derivatives in patients, based on unpublished and published reports available publicly on the internet as of May, 27, 2020.

The keywords “hydroxychloroquine”, “chloroquine”, “coronavirus”, “COVID-19” and “SARS-Cov-2” were used in the PubMed, Google Scholar and Google search engines without any restrictions as to date or language.

Twenty studies were identified involving 105,040 patients (19,270 treated patients) from nine countries (Brazil, China, France, Iran, Saudi Arabia, South Korea, Spain, and USA).

Big data observational studies were associated with conflict of interest, lack of treatment dosage and duration, and absence of favorable outcome.

Big data observational studies were associated with conflict of interest, lack of treatment dosage and duration, and absence of favorable outcome.

Clinical studies were associated with favorable outcomes and details on therapy. Among clinical studies, three of four randomized controlled trials reported a significant favorable effect.

Among clinical studies, a significant favorable summary effect was observed for duration of cough (Odds ratio (OR), 0.19, p = .00003), duration of fever (0.11, p = .039), clinical cure (0.21, p = .0495), death (0.32, p = 4.1×10-6) and viral shedding (0.43, p = .031). A trend for a favorable effect was noted for the outcome “death and/or ICU transfer” (0.29, p = .069) with a point estimate remarkably similar to that observed for death (∼0.3).

In conclusion, a meta-analysis of publicly available clinical reports demonstrates that chloroquine derivatives are effective to improve clinical and virological outcomes but, more importantly, it reduces mortality by a factor of 3 in patients infected with COVID-19.

Big data are lacking basic treatment definitions and are linked to conflict of interest.

In conclusion, a meta-analysis of publicly available clinical reports demonstrates that chloroquine derivatives are effective to improve clinical and virological outcomes but, more importantly, it reduces mortality by a factor 3 in patients infected with COVID-19. Big data are lacking basic treatment definitions and are linked to conflict of interest.

On Trend

Latest Stories

Palmer welcomes lift of hydroxychloroquine ban

Chief Health Officer (CHO) John Gerrard has now revoked the 2020 direction, stating on the Queensland Health website:
“I, Dr John Gerrard, Chief Health Officer, reasonably believe it is necessary to give the following direction pursuant to the powers under s362B of the Public Health Act 2005 to assist in contain, or to respond to, the spread of COVID-19 within the community.”
Mr Palmer has been a strong supporter of the use of hydroxychloroquine for the treatment of COVID-19, purchasing 37 million doses of the drug for Australians at the start of the outbreak.

Read More »

Dr. Harvey Risch: Hydroxychloroquine, Ivermectin, and Other Therapeutics Highly Effective in Early COVID Treatment

I’ve railed against this in the media that we are a part of, and the way that the propaganda reacts to this is, “Ignore it. Ignore all of this.” I’m saying this now because the general public has to be the one that gets angry. The general public should be furious at the way people have been treated in the country by suppression of these drugs, by that kind of website that suppresses the ability of doctors to practice medicine.

Read More »